Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 7/20 | 0.50 |
| ▸ | MME | P08473 | 3/20 | 0.50 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.47 |
| ▸ | CPA1 | P15085 | 1/20 | 0.47 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24435832 | 0.85 | ACE (0.48) | ACEMMEOPRD1CPA1ACE2 | |
| SCHEMBL24435980 | 0.83 | ACE (0.49) | ACEMMECPA1ACE2 | |
| SCHEMBL22457528 | 0.83 | ACE (0.49) | ACEMMECPA1ACE2 | |
| SCHEMBL24435839 | 0.83 | CTSS (0.51) | ACEMME | |
| SCHEMBL22457541 | 0.83 | MME (0.56) | ACEMMECPA1ACE2 | |
| SCHEMBL24435918 | 0.82 | REN (0.49) | ACEMMEOPRD1CPA1ACE2 | |
| Phenylalanyltyrosine SCHEMBL3037096 | 0.79 | MME (0.67) | ACEMMEOPRD1OPRM1OPRK1 | |
| Phenylalanyltyrosine SCHEMBL4282059 | 0.79 | MME (0.67) | ACEMMEOPRD1OPRM1OPRK1 | |
| SCHEMBL8695556 | 0.79 | MME (0.67) | ACEMMEOPRD1OPRM1OPRK1 | |
| Phenylalanyltyrosine SCHEMBL31255162 | 0.79 | MME (0.67) | ACEMMEOPRD1OPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12240871-B2 | Method for producing peptide compound | NISSAN CHEMICAL CORPORATION (JP) | 2025-03-04 | — | — | US | disclosed |
| US-20220153777-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND | NISSAN CHEMICAL CORPORATION (JP) | 2022-05-19 | — | — | US | disclosed |
| US-20220153777-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND | NISSAN CHEMICAL CORPORATION (JP) | 2022-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12240871-B2 | Method for producing peptide compound | NGLY1, NPPA, NPEPPS | ACE 982/4885MME 67/4885OPRD1 4389/4885 |
| US-20220153777-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND | NGLY1, NPPA, NPEPPS | ACE 982/4885MME 67/4885OPRD1 4389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.